TScan Therapeutics, Inc. (NASDAQ:TCRX) Sees Large Drop in Short Interest

TScan Therapeutics, Inc. (NASDAQ:TCRX) was the recipient of a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 2,000,000 shares, a drop of 20.6% from the December 31st total of 2,520,000 shares. Currently, 4.6% of the shares of the company are sold short. Based on an average trading volume of 403,800 shares, the days-to-cover ratio is currently 5.0 days.

Analyst Ratings Changes

Several research analysts recently commented on TCRX shares. Wedbush reiterated an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Monday, December 23rd. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research report on Wednesday, December 11th.

Hedge Funds Weigh In On TScan Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. bought a new position in shares of TScan Therapeutics in the fourth quarter worth about $32,000. Heck Capital Advisors LLC acquired a new position in TScan Therapeutics in the fourth quarter valued at approximately $61,000. SG Americas Securities LLC lifted its holdings in TScan Therapeutics by 31.2% in the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock valued at $62,000 after buying an additional 4,852 shares during the period. Dimensional Fund Advisors LP acquired a new position in TScan Therapeutics in the second quarter valued at approximately $70,000. Finally, The Manufacturers Life Insurance Company acquired a new position in TScan Therapeutics in the second quarter valued at approximately $90,000. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Price Performance

Shares of TScan Therapeutics stock traded down $0.14 during trading on Monday, hitting $2.43. 301,477 shares of the company’s stock traded hands, compared to its average volume of 294,022. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. The firm’s fifty day moving average price is $3.20 and its 200 day moving average price is $4.75. TScan Therapeutics has a twelve month low of $2.31 and a twelve month high of $9.69. The company has a market cap of $129.69 million, a PE ratio of -2.29 and a beta of 0.88.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.86 million. Analysts forecast that TScan Therapeutics will post -1.12 earnings per share for the current year.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.